You are here: Industry Insights > Bristol-Myers Squibb

News List

NICE backs use of Bristol-Myers Squibb's Opdivo via Cancer Drugs Fund for completely resected melanoma firstwordpharma
December 02, 2018
The National Institute for Health and Care Excellence issued a final appraisal document on Friday recommending use of Bristol-Myers Squibb's Opdivo (nivolumab) within the Cancer Drugs Fund (CDF) as an option for the adjuvant treatment of completely resect
BMS' Opdivo+Yervoy combo fails in small cell lung cancer pharmafile
November 28, 2018
Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as a maintenance treatment for extensive-stage
Bristol-Myers Squibb laying off 69 employees in Florida in push to 'focus resources' fiercepharma
November 19, 2018
After opening an office in Tampa, Florida, in 2014 and filling hundreds of positions, Bristol-Myers Squibb plans to lay off dozens of employees there early next year.
Bristol-Myers Squibb, Compugen Announce Clinical Collaboration americanpharmaceuticalreview
October 12, 2018
Bristol-Myers Squibb and Compugen announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb's pro
Bristol-Myers, AbbVie net FDA 'breakthrough' for myeloma drug Empliciti fiercepharma
August 27, 2018
The myeloma drug Empliciti is currently approved alongside Revlimid and dexamethasone for patients who have already received anywhere from one to three prior treatments.
Bristol-Myers Squibb's Opdivo secures a lung cancer niche with small-cell green light fiercepharma
August 20, 2018
Bristol-Myers Squibb may be trailing rival Merck in the non-small cell lung cancer market, but it’s landed a niche of its own in the small cell arena.
The day has come: Merck’s Keytruda surpasses Bristol-Myers Squibb’s Opdivo in Q2 sales fiercepharma
July 30, 2018
Merck & Co.’s blockbuster cancer drug Keytruda has delivered again in the second quarter, and this time, it has seized the PD-1/L1 crown from Bristol-Myers Squibb’s archrival Opdivo.
Q2 results roundup - 27 July pharmatimes
July 30, 2018
Amgen has posted higher sales in Q2 2018 boosted by double-dgitig growth from some of its recently launched products. Revenue rose by 4% to $6.1 billion, above forecasts $5.7 billion. CEO Robert Bradway noted that "our two most recently launched products,
Bristol-Myers Squibb, Tsinghua University pen drug discovery pact fiercebiotech
July 26, 2018
Bristol-Myers Squibb has teamed up with China’s Tsinghua University to discover drugs that hit novel cancer and autoimmune disease targets. The agreement tasks Tsinghua with discovering therapeutics that Bristol-Myers can then choose to license.
Bristol-Myers Squibb commercial chief Gordon jumps ship ahead of key Opdivo launch fiercepharma
July 24, 2018
Bristol-Myers Squibb is locked in some pretty big marketing battles—but it’ll have to soldier on without its commercial leader.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page